Northern Light Venture Capital
VC Fund
Beijing, China
Northern Light Venture Capital is a VC fund in Beijing focused on Health Care and Medical. Northern Light Venture Capital was founded by general partners Feng Deng and Yan Ke on January 1, 2005. Currently it is managed by five Managing Directors. It manages approximately US$ 1.5 billion in committed capital with 4 US$ funds and 4 RMB funds, investing in more than 180 portfolio companies and seed investments to date.NLVC is led by apartnership of accomplished local Chinese and ""returnee"" executives (""returnees"" are those who grew up in mainland China but studied or worked abroad before returning) with significant investing and entrepreneurial accomplishments. Its management team includes Feng Deng, former member of the board at NetScreen (a pioneering IT security firm), Yan Ke, vice President of Netscreen, and Lei Yang, chairman of Vantage Point Venture Partners.NLVC is a China concept venture capital firm focused on early and growth stage opportunities which targets businesses that leverage China’s industrial, economic, or human resources to build exceptional, lasting enterprises in the global economy.NLVC focuses on early and growth stage opportunities in information technology, new media, TMT, clean technologies, consumer service and healthcare. Portfolio companies include Meituan.com, Kaixin001.com, Gogo.com, redbaby.com, MasaMaso.com, and Velo City.
- Total investments:
- 279
- Last investment:
- Lead investor:
- 27%
- Fund size:
- $375M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Northern Light Venture Capital invests in
Stages Northern Light Venture Capital invests in
Countries Northern Light Venture Capital invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $1.3M–$100M
- Series A
- $4.3M–$67M
- Series B
- $11M–$62M
Investment Focus
Industry
- Health Care 45 (16%)
- Medical 37 (13%)
- Biotechnology 35 (13%)
- Manufacturing 26 (9%)
- Internet 21 (8%)
Stage
- Series A 70 (25%)
- Series B 66 (24%)
- Seed 38 (14%)
- Series C 28 (10%)
- Angel 17 (6%)
Country
- China 170 (61%)
- United States 29 (10%)
- South Korea 6 (2%)
- Germany 1 (0%)
- Singapore 1 (0%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Figo Zhang
Partner
|
Partner | Total investments: 1 | Find email | |
Feng Deng
Founding General Partner
|
Founding General Partner | Total investments: 27 | Find email | |
Lixin Li
Managing Director
|
Managing Director | Total investments: 2 | Find email | |
Lu Lin
Executive Director
|
Executive Director | Total investments: 2 | Find email | |
Pandy Song
Associate
|
Associate | Total investments: 0 | Find email | |
| See all 12 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
NoizAI
|
Noiz AI is a product that offers highly expressive, lifelike speech synthesis, leading the industry in cost, efficiency, and customization. Use cases include TTS, voice cloning, video dubbing, and video translation. | Seed / Aug 10, 2026 | |
SuperMagnetic New Energy
|
SuperMagnetic New Energy is a cutting-edge innovation center and engineering incubator. | Angel / Jun 29, 2026 | |
Blue Pivot Energy Technology
|
Blue Pivot Energy Technology is a nuclear energy technology company focused on the independent development and commercialization of integrated water-cooled small modular reactors (SMRs). | Seed / Jun 11, 2026 | |
|
SuperMagnetic New Energy
|
SuperMagnetic New Energy is a cutting-edge innovation center and engineering incubator. | Angel / Jan 16, 2026 | |
Vibrant
|
Vibrant develops an AI drug development platform to focus on building immune system-related drug pipelines. The company will use artificial intelligence algorithms to accelerate the efficiency of drug development in various aspects such as target discovery, drug design, and drug efficacy evaluation; at the same time, the company expects tocontinuously improve the success rate of drug development through sustainable data accumulation and algorithm optimization.It was founded and headed by Dr. Wang Luquan and is based in Guangzhou, Guangdong, China. | $61M / Jan 12, 2026 | |
Spiro Medical
|
Spiro Medical is a medical device company developing a groundbreaking Pulmonary Neuromodulation (PNM) System for asthma treatment. The company offers a drug-free approach to controlling severe, chronic airway diseases through its Spiro Neuromodulation System. | $67M / Series A / Jan 07, 2026 | |
BV Laser
|
BV Laser is a manufacturer of medical beauty equipment. | $14.2M / Series C / Dec 15, 2025 | |
|
Sanegene Bio
|
Sanegene Bio is currently operating in stealth mode. | $110M / Series B / Dec 08, 2025 | |
Kind Pharmaceutical
|
Kind Pharmaceutical is a clinical-stage biopharmaceutical company that focuses on the discovery and development of anemia drugs. The company was founded in 2013 and is headquartered in Redwood City, California, United States. | $56.2M / Series C / Nov 12, 2025 | |
HiDiamond Biotechnology
|
HiDiamond Biotechnology is a biopharmaceutical company offering research and development for therapeutic products and molecular entities. | $14.1M / Seed / Sep 17, 2025 | |
| See all 279 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Northern Light Venture Capital invest in?
Northern Light Venture Capital invests primarily in Health Care, Medical and Biotechnology startups, most often at Series A and Series B stage. Most of the 279 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Northern Light Venture Capital's check size?
Northern Light Venture Capital typically joins rounds of $1.3M–$100M at Seed, $4.3M–$67M at Series A and $11M–$62M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Northern Light Venture Capital participates in.
How do I contact Northern Light Venture Capital?
Public channels for Northern Light Venture Capital include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Northern Light Venture Capital?
The team at Northern Light Venture Capital includes Figo Zhang (Partner), Feng Deng (Founding General Partner) and Lixin Li (Managing Director), among 12 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
